Last reviewed · How we verify

ABSK021 — Competitive Intelligence Brief

ABSK021 (ABSK021) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K/AKT/mTOR pathway inhibitor. Area: Oncology.

phase 2 PI3K/AKT/mTOR pathway inhibitor PI3K/AKT/mTOR pathway Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ABSK021 (ABSK021) — Abbisko Therapeutics Co, Ltd. ABSK021 is a small molecule targeting the PI3K/AKT/mTOR pathway.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ABSK021 TARGET ABSK021 Abbisko Therapeutics Co, Ltd phase 2 PI3K/AKT/mTOR pathway inhibitor PI3K/AKT/mTOR pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K/AKT/mTOR pathway inhibitor class)

  1. Abbisko Therapeutics Co, Ltd · 1 drug in this class
  2. Suzhou Abogen Biosciences Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABSK021 — Competitive Intelligence Brief. https://druglandscape.com/ci/absk021. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: